Genomics and Drug Development
Group Members
Dr. Mekdes Megeressa, Ph.D. Research Associate
Ph.D. Pharmaceutical Sciences, Chapman University, Irvine, California, USA
Dr. Seema Saroj, Ph.D.
Research Associate
Ph.D. Pharmaceutics, The Maharaja Sayajirao University, India
External Position: Research Associate, Alembic Pharmaceuticals, India
Neha S. Tomar, Ph.D. (In progress)
Research Assistant
Ph.D. (ongoing) Neuroscience, University of Salford, UK
Ara V. Abbott, MS
Research Assistant
MS Individualized Genomics and Health, Johns Hopkins University, Baltimore, MD, USA
Heba Fleihan, MS
Research Assistant
MS Biochemistry and Molecular Genetics, American University of Beirut, Lebanon
Research Coordinator
Elisa Hampson
admin@camcid.org
Research Focus
Genomics, especially high-performance sequencing and characterization of expressed human genes, has provided new possibilities for drug discovery. We perform literature reviews and data analysis in the areas of genomics, proteomics, bioinformatics, drug-protein, drug-membrane binding, and different drug delivery systems
Our Genomics and Drug Development group carries out researches in the following areas:
- DNA sequencing methods and bioinformatics
- Genetic diagnosis of disease
- Next-generation sequencing (NGS)
- Drug Development
Projects
Endometrial Cancer: Biomarkers and Potential Therapeutic Targets
Endometrial cancer (EC) is the most commonly diagnosed cancer of the female reproductive system. Similar to other forms of cancer, early detection, and accurate intervention is of vital importance. This research aims to identify potential biomarkers and significant alterations in gene expression by conducting RNA-seq analysis of publicly available cancer datasets. Additionally, successful pregnancy has been identified by multiple studies as a preventative factor for EC. Our research also aims to explore the mechanisms during a successful pregnancy that can potentially mitigate EC risks.